Ian F. Hermans

This paper designs an mRNA vaccine with fused SARS-CoV-2 RBDs from different variants to elicit cross-reactive antibodies without extensive somatic hypermutation.

This study optimizes an mRNA vaccine to enhance liver Trm cell induction by reducing type I interferon responses through improved manufacturing.

The paper identifies temporal expression patterns of liver-stage malaria antigens and shows that combining antigens with different temporal profiles improves vaccine efficacy.

This paper develops genetically engineered mouse cell line models (GEM-CLeMs) of glioma that recapitulate key phenotypes of low- and high-grade gliomas, offering a more accurate model of the tumor microenvironment than existing cell lines.

This paper shows that tarloxotinib, a hypoxia-activated prodrug, reduces tumor hypoxia and enhances immune checkpoint inhibitor efficacy through TLR9-dependent mechanisms in multiple tumor models.